Blood pressure control and components of the metabolic syndrome: The GOOD survey

Cardiovascular Diabetology

Volumn 8, Issue , 2009, Pages 51-

  Zidek, Walter ^a   Naditch Brûlé, Lisa ^b   Perlini, Stefano ^c   Farsang, Csaba ^d   Kjeldsen, Sverre E ^e  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b SANOFI   (France)

^c UNIVERSITY OF PAVIA   (Italy)

^d Szent Imre Hospital   (Hungary)

^e ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ARTICLE; BLOOD PRESSURE REGULATION; BODY MASS; CARDIOLOGIST; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIABETES MELLITUS; DRUG RESPONSE; DYSLIPIDEMIA; ESSENTIAL HYPERTENSION; FEMALE; GENERAL PRACTITIONER; HEALTH SURVEY; HUMAN; HYPERTRIGLYCERIDEMIA; IMPAIRED GLUCOSE TOLERANCE; MAJOR CLINICAL STUDY; MALE; MEDICAL SPECIALIST; METABOLIC SYNDROME X; OBESITY; PRACTICE GUIDELINE; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE;

ADULT; AGED; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; BODY MASS INDEX; COMORBIDITY; CREATININE; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS; DRUG RESISTANCE; EUROPE; FEMALE; HABITS; HEALTH SURVEYS; HUMANS; HYPERTENSION; INTRA-ABDOMINAL FAT; LIFE STYLE; LIPIDS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; OBESITY; POLYPHARMACY; RISK FACTORS; WAIST CIRCUMFERENCE;

EID: 70449337171     PISSN: None     EISSN: 14752840     Source Type: Journal    
DOI: 10.1186/1475-2840-8-51     Document Type: Article

References (26)

1. Kjeldsen SE, Naditch-Brule L, Perlini S, Zidek W, Farsang C. Increased prevalence of metabolic syndrome in uncontrolled hypertension across Europe: the Global Cardiometabolic Risk Profile in Patients with hypertension disease survey. J Hypertens 2008, 26:2064-2070. 10.1097/HJH.0b013e32830c45c3, 18806632.
2. Farsang C, Naditch-Brule L, Perlini S, Zidek W, Kjeldsen SE. Inter-regional comparisons of the prevalence of cardiometabolic risk factors in patients with hypertension in Europe: the GOOD survey. J Hum Hypertens 2009, 23:316-324. 10.1038/jhh.2008.136, 19005476.
3. Ritchie SA, Ewart MA, Perry CG, Connell JM, Salt IP. The role of insulin and the adipocytokines in regulation of vascular endothelial function. Clin Sci (Lond) 2004, 107:519-532.
4. Aldhahi W, Hamdy O. Adipokines, inflammation, and the endothelium in diabetes. Curr Diab Rep 2003, 3:293-298. 10.1007/s11892-003-0020-2, 12866991.
5. Guerre-Millo M. Adipose tissue and adipokines: for better or worse. Diabetes Metab 2004, 30:13-19. 10.1016/S1262-3636(07)70084-8, 15029093.
6. Lau DC, Dhillon B, Yan H, Szmitko PE, Verma S. Adipokines: molecular links between obesity and atheroslcerosis. Am J Physiol Heart Circ Physiol 2005, 288:H2031-2041. 10.1152/ajpheart.01058.2004, 15653761.
7. Chow WS, Cheung BM, Tso AW, Xu A, Wat NM, Fong CH, Ong LH, Tam S, Tan KC, Janus ED. Hypoadiponectinemia as a predictor for the development of hypertension: a 5-year prospective study. Hypertension 2007, 49:1455-1461. 10.1161/HYPERTENSIONAHA.107.086835, 17452504.
8. Ouchi N, Ohishi M, Kihara S, Funahashi T, Nakamura T, Nagaretani H, Kumada M, Ohashi K, Okamoto Y, Nishizawa H. Association of hypoadiponectinemia with impaired vasoreactivity. Hypertension 2003, 42:231-234. 10.1161/01.HYP.0000083488.67550.B8, 12860835.
9. Ouedraogo R, Gong Y, Berzins B, Wu X, Mahadev K, Hough K, Chan L, Goldstein BJ, Scalia R. Adiponectin deficiency increases leukocyte-endothelium interactions via upregulation of endothelial cell adhesion molecules in vivo. J Clin Invest 2007, 117:1718-1726. 10.1172/JCI29623, 1878515, 17549259.
10. Tan KC, Xu A, Chow WS, Lam MC, Ai VH, Tam SC, Lam KS. Hypoadiponectinemia is associated with impaired endothelium-dependent vasodilation. J Clin Endocrinol Metab 2004, 89:765-769. 10.1210/jc.2003-031012, 14764794.
11. Hattori Y, Hattori S, Akimoto K, Nishikimi T, Suzuki K, Matsuoka H, Kasai K. Globular adiponectin activates nuclear factor-kappaB and activating protein-1 and enhances angiotensin II-induced proliferation in cardiac fibroblasts. Diabetes 2007, 56:804-808. 10.2337/db06-1405, 17327451.
12. Chen H, Montagnani M, Funahashi T, Shimomura I, Quon MJ. Adiponectin stimulates production of nitric oxide in vascular endothelial cells. J Biol Chem 2003, 278:45021-45026. 10.1074/jbc.M307878200, 12944390.
13. Quehenberger P, Exner M, Sunder-Plassmann R, Ruzicka K, Bieglmayer C, Endler G, Muellner C, Speiser W, Wagner O. Leptin induces endothelin-1 in endothelial cells in vitro. Circ Res 2002, 90:711-718. 10.1161/01.RES.0000014226.74709.90, 11934840.
14. Bouloumie A, Marumo T, Lafontan M, Busse R. Leptin induces oxidative stress in human endothelial cells. FASEB J 1999, 13:1231-1238.
15. Esposito K, Pontillo A, Di Palo C, Giugliano G, Masella M, Marfella R, Giugliano D. Effect of weight loss and lifestyle changes on vascular inflammatory markers in obese women: a randomized trial. JAMA 2003, 289:1799-1804. 10.1001/jama.289.14.1799, 12684358.
16. Ahima RS, Flier JS. Adipose tissue as an endocrine organ. Trends Endocrinol Metab 2000, 11:327-332. 10.1016/S1043-2760(00)00301-5, 10996528.
17. Jones DW, Kim JS, Andrew ME, Kim SJ, Hong YP. Body mass index and blood pressure in Korean men and women: the Korean National Blood Pressure Survey. J Hypertens 1994, 12:1433-1437. 10.1097/00004872-199412000-00018, 7706705.
18. Hall JE, Hildebrandt DA, Kuo J. Obesity hypertension: role of leptin and sympathetic nervous system. Am J Hypertens 2001, 14:103S-115S. 10.1016/S0895-7061(01)02077-5, 11411745.
19. Hall JE, Crook ED, Jones DW, Wofford MR, Dubbert PM. Mechanisms of obesity-associated cardiovascular and renal disease. Am J Med Sci 2002, 324:127-137. 10.1097/00000441-200209000-00003, 12240710.
20. Garrison RJ, Kannel WB, Stokes J, Castelli WP. Incidence and precursors of hypertension in young adults: the Framingham Offspring Study. Prev Med 1987, 16:235-251. 10.1016/0091-7435(87)90087-9, 3588564.
21. Cutler JA, Sorlie PD, Wolz M, Thom T, Fields LE, Roccella EJ. Trends in hypertension prevalence, awareness, treatment, and control rates in United States adults between 1988-1994 and 1999-2004. Hypertension 2008, 52:818-827. 10.1161/HYPERTENSIONAHA.108.113357, 18852389.
22. Hayashi T, Boyko EJ, Leonetti DL, McNeely MJ, Newell-Morris L, Kahn SE, Fujimoto WY. Visceral adiposity is an independent predictor of incident hypertension in Japanese Americans. Ann Intern Med 2004, 140:992-1000.
23. Wildman RP, Sutton-Tyrrell K, Newman AB, Bostom A, Brockwell S, Kuller LH. Lipoprotein levels are associated with incident hypertension in older adults. J Am Geriatr Soc 2004, 52:916-921. 10.1111/j.1532-5415.2004.52258.x, 15161455.
24. Nofer JR, Giet M, Tolle M, Wolinska I, von Wnuck Lipinski K, Baba HA, Tietge UJ, Godecke A, Ishii I, Kleuser B. HDL induces NO-dependent vasorelaxation via the lysophospholipid receptor S1P3. J Clin Invest 2004, 113:569-581. 338256, 14966566.
25. Redon J, Cifkova R, Laurent S, Nilsson P, Narkiewicz K, Erdine S, Mancia G. The metabolic syndrome in hypertension: European society of hypertension position statement. J Hypertens 2008, 26:1891-1900. 10.1097/HJH.0b013e328302ca38, 18806611.
26. Hanefeld M, Koehler C, Gallo S, Benke I, Ott P. Impact of the individual components of the metabolic syndrome and their different combinations on the prevalence of atherosclerotic vascular disease in type 2 diabetes: the Diabetes in Germany (DIG) study. Cardiovasc Diabetol 2007, 6:13. 10.1186/1475-2840-6-13, 1871572, 17462080.